Company
Aravive
Claim, correct or request removal
Record updated 20 September 2026
About
Aravive is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. Its lead product candidate, Batiraxcept (formerly AVB-500), is an ultra-high-affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, inhibiting metastasis, tumour growth, and restoring sensitivity to anti-cancer agents.
Loading relationship preview